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Respiratory chain deficiency in
nonmitochondrial disease
ABSTRACT
Objective: In this study, we report 5 patients with heterogeneous phenotypes and biochemical
evidence of respiratory chain (RC) deficiency; however, the molecular diagnosis is not mitochon-
drial disease.
Methods: The reported patients were identified from a cohort of 60 patients in whom RC enzyme
deficiency suggested mitochondrial disease and underwent whole-exome sequencing.
Results: Five patients had disease-causing variants in nonmitochondrial disease genes ORAI1,
CAPN3, COLQ, EXOSC8, and ANO10, which would have been missed on targeted next-
generation panels or on MitoExome analysis.
Conclusions: Our data demonstrate that RC abnormalities may be secondary to various cellular
processes, including calcium metabolism, neuromuscular transmission, and abnormal messenger
RNA degradation. Neurol Genet 2015;1:e6; doi: 10.1212/NXG.0000000000000006
GLOSSARY
ARE 5 AU-rich element; CoQ10 5 coenzyme Q10; LGMD2A 5 limb-girdle muscular dystrophy type 2A;mRNA 5 messenger
RNA; mtDNA 5 mitochondrial DNA; RC 5 respiratory chain.
Respiratory chain (RC) complex defects are hallmarks of mitochondrial disease that often pro-
vide the first diagnostic evidence for a mitochondrial disorder and guide subsequent DNA anal-
ysis of the mitochondrial DNA (mtDNA) and nuclear genes encoding mitochondrial proteins.1
In a substantial proportion of cases, it is not possible to reach a molecular diagnosis, and it is
assumed that most of these patients carry undetected mutations in genes coding for mitochon-
drial proteins. This report presents 5 patients with heterogeneous phenotypes and biochemical
features of RC deficiency; however, the molecular diagnosis is not mitochondrial disease.
METHODS Patients with biochemical evidence of RC deficiencies measured by standard methods in accredited laboratories in
whom mtDNA mutations had been excluded were selected from a cohort of 60 patients for whole-exome sequencing.1 The
diagnosis of a mitochondrial RC deficiency was based on the recently published consensus paper by the Mitochondrial Medicine
Society (USA).2 Coverage and depth statistics of exome sequencing for each patient and the bioinformatic prediction for each mutation
are listed in tables e-1 and e-2 at Neurology.org/ng.
Standard protocol approvals, registrations, and patient consents. Informed consent was obtained from all participants in accor-
dance with protocols approved by local institutions and research ethics committees.
RESULTS Patient 1 presented with generalized muscular hypotonia, failure to thrive, liver dysfunction, atrial
septal defect, and severe immunodeficiency. Based on the biochemical defect of complex I (50%) and IV
(80% rest-activity) in skeletal muscle, mitochondrial disease was suggested. Exome sequencing identified a
homozygous mutation c.587T.C, p.Leu196Pro in the ORAI1 gene, which is predicted to be deleterious with
6 different prediction programs (table e-2) and is located next to a pathogenic mutation (p.Leu194Pro).3 ORAI1
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encodes a calcium release-activated calcium channel
protein that allows cellular calcium influx3 and may
alter mitochondrial calcium metabolism, leading to
RC deficiency. Autosomal recessive mutations in
ORAI1 have previously been described in association
with severe combined immunodeficiency and
Figure Detailed clinical andmolecular genetic characteristics of patients in this study and localization of nuclear mutant proteins resulting in
respiratory chain deficiencies
(A) Table of clinical andmolecular genetic characteristics of 5 patientswith heterogeneous phenotypes and biochemical features of respiratory chain deficiency.
(B) Crystal structure of the human exosome complex involved in RNAmetabolism. EXOSC8 highlighted in pink. ORAI1, calcium channel located on the cell mem-
brane. ANO10, calcium-activated chloride channel located on the cell membrane. CAPN3, an intracellular calcium-activated neutral protease isoform located
within the sarcomere. COLQ protein, a collagen-like subunit associated with acetylcholinesterase in skeletal muscle. CoQ10 5 coenzyme Q10.
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congenital myopathy and in dominantly inherited
tubular aggregate myopathy with hypocalcemia.3
Patient 2 presented with a juvenile-onset slowly
progressive myopathy and limb-girdle muscle weak-
ness. The clinical diagnosis of a mitochondrial myop-
athy was based on the detection of cytochrome c
oxidase–negative fibers and decreased complex IV
activity in muscle (80% rest-activity). A known path-
ogenic homozygous c.1715G.A, p.Arg572Gln
mutation was detected in CAPN3 encoding a skeletal
muscle-specific intracellular calcium-activated neutral
protease, and its deficiency leads to oxidative stress
and potentially a secondary RC deficiency.4 This is a
previously published pathogenic mutation and the
only variant that segregated with the disease in
the family. CAPN3 mutations are common causes
of limb-girdle muscular dystrophy type 2A
(LGMD2A).4 Muscle biopsy shows a dystrophic
pattern; however, disorganized mitochondria and
reduced complex V levels were occasionally reported
in a few patients with LGMD2A.4
Patient 3 presented with axial muscle weakness,
ptosis, respiratory failure requiring ventilation, and
reduced IV (80% rest-activity) and borderline com-
plex I activities. We detected a homozygous frame-
shift mutation c.636delA, p.Lys212fs in the COLQ
gene. Mutations of the acetylcholinesterase collagen-
like tail subunit gene (COLQ) cause congenital
myasthenic syndromes due to the deficiency of ace-
tylcholine esterase at the synaptic endplate.5 The clin-
ical phenotype includes hypotonia, muscle weakness,
delayed motor development, ophthalmoparesis, and
respiratory failure. No involvement of mitochondria
has been suggested in previous patients to date.5
Patient 4 belonged to a large Hungarian Roma
pedigree presenting with hypomyelination, hypopla-
sia of the cerebellum and corpus callosum, and spinal
muscular atrophy. Muscle biopsy revealed reduced
complex I (60% rest-activity) and IV (80% rest-
activity). We identified a homozygous c.815G.C,
p.Ser272Thr mutation in a novel disease gene
EXOSC8 encoding an exosome subunit involved in
AU-rich element (ARE)-containing messenger RNA
(mRNA) degradation, and the altered myelination
was due to abnormal degradation of ARE myelin pro-
teins.6 The pathogenicity of the mutation was sup-
ported by the absence of EXOSC8 protein in
myoblasts of the patient and by segregation with the
disease in the large pedigree.6 A secondary RC defect in
these patients may be related to abnormal degradation
of ARE mRNAs of mitochondrial disease genes.
Patient 5 presented in childhood with epilepsy and
learning difficulties and developed cerebellar ataxia,
brisk reflexes, and nystagmus from age 45 years.
Complex III defect (60% rest-activity) and low coen-
zyme Q10 (CoQ10) (60% of low normal) were
detected in her muscle. We identified compound het-
erozygous pathogenic mutations in ANO10
(c.132_133insT, p.Asp45Arg fs*53 and c.1843G.A,
p.Asp615Asn).7 The pathogenicity of the missense
variant c.1843G.A, p.Asp615Asn has been confirmed
by its detection in additional patients.8 CoQ10 supple-
mentation resulted in clinical improvement, emphasiz-
ing the importance of low CoQ10 in the
pathomechanism.7 ANO10 encodes an anoctamin pro-
tein forming calcium-activated chloride channels, imply-
ing that an abnormal calcium metabolism may cause
mitochondrial dysfunction in ANO10 deficiency.7
DISCUSSION Typically, RC defects are associated
with mutations in the mtDNA or in nuclear genes
affecting mitochondrial proteins. The patients we pre-
sent here had disease-causing (previously reported or
nonsense) variants in nonmitochondrial disease
genes, which would have been missed on targeted
next-generation panels or on MitoExome analysis.9
Our data demonstrate that RC abnormalities may be
secondary to various cellular processes, including
calcium metabolism, neuromuscular transmission,
and abnormal mRNA degradation; however, the role
of mitochondria in these diseases needs further
investigation (figure). Secondary RC defects in
patients with neurogenetic disease have previously
been reported. For example, Alexander disease is
caused by nuclear mutations encoding non-RC chain
proteins, but patients exhibit biochemical and MRI
findings typically found with RC abnormalities.10
Faced with increasing numbers of published
disease-causing variants, improved and more accessi-
ble sequencing techniques, and more comprehensive
phenotype characterization, the clinician should keep
an open mind when approaching genetic testing and
not limit testing to predicted disease-causing variants
in suspicion of mitochondrial disease.
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